NIMESULIDE IN ACUTE AND CHRONIC PAIN: EMPHASIS ON SAFETY ISSUES


Cite item

Full Text

Abstract

The article considers in detail the pathogenetic mechanisms of action, efficacy and safety of nonsteroidal anti-inflammatory drugs (NSAIDs) in acute and chronic pain. Particular attention is paid to gastrointestinal and cardiovascular complications. The data of international and domestic studies on the use of nimesulide in clinical practice, confirming its efficacy and good tolerability, are presented.

References

  1. Насонов Е.Л., Насонова В.А. Фармакотерапия боли: взгляд ревматолога // Consilium medicum 2000. № 2 (12). С. 7-14.
  2. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М., 2009. 167 с.
  3. Боль (практическое руководство для врачей) / Под ред. Н.Н. Яхно, М.Л. Кукушкина. М., 2012. 512 c.
  4. Hochman J, French M, Bermingham S, Hawker G. The nerve of osteoarthritis pain. Arthritis Care Res (Hoboken) 2010;62(7):1019-23.
  5. Arendt-Nielsen L, Nie H, Laursen M, et al. Sensitization in patients with painful knee osteoarthritis. Pain 2010;149(3):573-81.
  6. Camu F. The role of COX-2 inhibitors in pain modulation. Drug 2003;63:1-7.
  7. Dembo G, Park S, Kharasch E. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology 2005;102(2):409-15.
  8. McCrory C, Fitzgerald D. Spinal prostaglandin formation and pain perception following thoracotomy: a role for cyclooxygenase-2. Chest 2004;125(4):1321-27.
  9. Tassorelli C, Greco R, Sandrini G, Nappi G. Central components of the analgesic/antihyperalgesic effect of nimesulide: studies in animal models of pain and hyperalgesia. Drugs 2003;63(1):9-22.
  10. Mehta V, Johnston A, Cheung R, et al. Intravenous parecoxib rapidly leads to COX-2 inhibitory concentration of valdecoxib in the central nervous system. Clin Pharmacol Ther 2008;83(3):430-35.
  11. Bianchi M, Martucci C, Ferrario P, et al. Increased Tumor Necrosis Factor-alfa and Prostaglandin E2 Concentrations in the Cerebrospinal Fluid of Rats with Inflammatory Hyperalgesia: The Effects of Analgesic Drugs. Anest Analg 2007;104:949-54.
  12. Lee Y, Wolfe F, Michaud K. Patterns of Pain Medication Use Among Rheumatoid Arthritis Patients From 2000-2010. Arthritis & Rheumatism, 2011;63(10):159-60.
  13. Singh G. Recent consideration in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105:31-38.
  14. Lanas A. Prevention and treatment of NSAID-induced gastrointestinal injury. Curr Treat Options Gastroenterol 2006;9:147-56.
  15. Каратеев А.Е., Насонова В.А. Развитие и рецидивирование язв желудка и двенадцатиперстной кишки у больных, принимающих нестероидные противовоспалительные препараты: влияние стандартных факторов риска // Тер. архив 2008. № 5. С. 62-66.
  16. Hochman J, Shah N. What Price Pain Relief? Circulation 2006;113:2868-70.
  17. Hermann M. Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Curr Rheumatol Rep 2009;11(1):31-35.
  18. Fosbøl E, Folke F, Jacobsen S, et al. Cause-Specific Cardiovascular Risk Associated With Nonsteroidal Antiinflammatory Drugs Among Healthy Individuals. Circ Cardiovasc Qual Outcomes 2010;3:395-405.
  19. McGettigan P, Henry D. Cardiovascular risk with nonsteroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;doi: 10.1371/journal.pmed.1001098.
  20. Aw T-J, Haas S, Liew D. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165:490-96.
  21. Lanas A, Tornero J, Zamorano J. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis 2010;69(8):1453-58.
  22. Насонов Е.Л. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой // Клин. фармакол. терапия 2003. №12 (1). С. 64-69.
  23. Барскова В.Г. Письмо редактора // Совр. ревматол. 2011. № 2. С. 82-83.
  24. Mattia C, Ciarcia S, Muhindo A, Coluzzi F. Nimesulide: 25 years later. Minerva Med 2010;101(4):285-93.
  25. Насонов Е.Л. Эффективность и переносимость нестероидного противовоспалительного препарата. Нимесулид: новые данные // РМЖ 2001. № 15. С. 6-8.
  26. Rainsford K. Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide. Inflammopharmacology 2006;14(3-4):120-37.
  27. Bennett A. Nimesulide a well established cyclooxygenase-2 inhibitor with many other pharmacological properties relevant to inflammatory diseases. In: Therapeutic Roles of Selective COX-2 Inhibitors. Editors Vein JR, Botting RM. William Harvey Press2001:524-540.
  28. Wober W, Rahlfs V, Buchl N, et al. Comparative efficacy and safety of the non-steroidal anti-inflammatory drugs nimesulide and diclofenac in patients with acute subdeltoid bursitis and bicipital tendinitis. Int J Clin Pract 1998;52(3):169-75.
  29. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine 2000;25(12):1579-85.
  30. Konstantinovic L, Kahjun Z, Milovanovic A, et al. Acute low back pain with radiculopathy: a double-blind, randomized, placebo-controlled study. Photomed laser surg 2010;28(4):555-60.
  31. Lücker P, Pawlowski C, Friedrich I, et al. Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee. Eur J Rheumatol Inflamm 1994;14(2):29-38.
  32. Huskisson E, Macciocchi A, Rahlfs V, et al. Nimesulide versus diclofenac in the treatment of osteoarthritis of the hip or knee: an active controlled equivalence study. Curr Ther Res 1999;60:253-65.
  33. Kriegel W, Korff K, Ehrlich J, et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract 2001;55(8):510-14.
  34. Bradbury F. How important is the role of the physician in the correct use of a drug? An observational cohort study in general practice. Int J Clin Pract 2004;144:27-32.
  35. Conforti A, Leone R, Moretti U, et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf 2001;24:1081-90.
  36. Laporte J, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Safety 2004;27:411-20.
  37. Helin-Salmivaara A, Virtanen A, Veslainen R, et al. NSAID use and the risk of hospitalisation for first myocardial infarction in the general population: a national case-control study from Finland. Eur Heart 2006;27:1657-63.
  38. Каратеев А.Е. Российский опыт применения нимесулида: обзор клинических испытаний // Consilium medicum 2011. № 13 (9). С. 89-95.
  39. Каратеев А.Е., Алексеева Л.И., Братыгина Е.А., Аширова Т.Б. Оценка частоты развития побочных эффектов при длительном применении нимесулида в реальной клинической практике // РМЖ 2009. №17 (21). С. 1466-72.
  40. Каратеев А.Е., Насонова В.А. НПВС-ассоциированная гепатопатия: проблема нимесулида // Научн. практ. ревматол. 2004. № 1. С. 34-37.
  41. Каратеев А.Е., Барскова В.Г. Безопасность нимесулида: эмоции или взвешенная оценка? // Consilium medicum 2007. № 9. С. 60-64.
  42. Rainsford K. Nimesulide - a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006;22(6):1161-70.
  43. HELSINN's response. На сайте: HELSINN, 2002, 12. На сайте: http://www.pharmabiz.com.
  44. Irish Board Suspends Marketing of Drugs Containing Nimesulide На сайте: http://www.imb.ie.
  45. Press release. European Medicines Agency recommends restricted use of nimesulid-containing medicinal products. Doc. Ref. EMEA/432604/2007 На сайте: http://www.emea.europa.eu.
  46. Press release. 23/06/2011 European Medicines Agency concludes review of systemic nimesulide-containing medicines. На сайте: http://www.ema.europa.eu/ema/
  47. Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in patient treated with COX-2 selective inhibitors or nonselective NSAIDs: A case/noncase analysis of spontaneous reports. Clinical Therapeutics 2006;28(8):1123-32.
  48. Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003;327:18-22.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies